Recombinant Human CDK8, MYC/DDK-tagged
Cat.No. : | CDK8-10H |
Product Overview : | Recombinant Human CDK8, fused with C-terminal MYC/DDK, was expressed in HEK293 cells. |
- Specification
- Gene Information
- Related Products
- Download
Description : | The protein encoded by this gene is a member of the cyclin-dependent protein kinase (CDK) family. CDK family members are highly similar to the gene products of Saccharomyces cerevisiae cdc28, and Schizosaccharomyces pombe cdc2, and are known to be important regulators of cell cycle progression. This kinase and its regulatory subunit cyclin C are components of the RNA polymerase II holoenzyme complex, which phosphorylates the carboxy-terminal domain (CTD) of the largest subunit of RNA polymerase II. This kinase has also been shown to regulate transcription by targeting the CDK7/cyclin H subunits of the general transcription initiation factor IIH (TFIIH), thus providing a link between the 'Mediator-like' protein complexes and the basal transcription machinery. |
Source : | HEK293 cells |
Species : | Human |
Tag : | Myc&DDK |
Molecular Mass : | 53.1 kDa |
Purity : | > 80% as determined by SDS-PAGE and Coomassie blue staining |
Concentration : | >50 ug/mL as determined by microplate BCA method |
Storage Buffer : | 25 mM Tris.HCl, pH 7.3, 100 mM glycine, 10% glycerol. |
Gene Name : | CDK8 cyclin-dependent kinase 8 [ Homo sapiens (human) ] |
Official Symbol : | CDK8 |
Synonyms : | cyclin-dependent kinase 8; K35; MGC126074; MGC126075; protein kinase K35; CDK8 protein kinase; cell division protein kinase 8; EC 2.7.11.22,EC 2.7.11.23; Protein kinase K35; CDK8; OTTHUMP00000018158; Mediator complex subunit CDK8; Mediator of RNA polymerase II transcription subunit CDK8 |
Gene ID : | 1024 |
mRNA Refseq : | NM_001260 |
Protein Refseq : | NP_001251 |
MIM : | 603184 |
UniProt ID : | P49336 |
Chromosome Location : | 13q12 |
Pathway : | Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants; Developmental Biology; Fatty acid, triacylglycerol, and ketone body metabolism |
Function : | ATP binding; RNA polymerase II carboxy-terminal domain kinase activity; cyclin-dependent protein serine/threonine kinase activity; protein binding |
Products Types
◆ Recombinant Protein | ||
CDK8-1039H | Active Recombinant Human CDK8 Protein, His-Tagged | +Inquiry |
CDK8-1038H | Active Recombinant Human CDK8 Protein, GST-Tagged | +Inquiry |
CDK8-1531M | Recombinant Mouse CDK8 Protein, His (Fc)-Avi-tagged | +Inquiry |
Cdk8-2091M | Recombinant Mouse Cdk8 Protein, Myc/DDK-tagged | +Inquiry |
CDK8-616R | Recombinant Rhesus Macaque CDK8 Protein, His (Fc)-Avi-tagged | +Inquiry |
◆ Lysates | ||
CDK8-7620HCL | Recombinant Human CDK8 293 Cell Lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Reviews
- Q&As
Customer Reviews (3)
Write a reviewThe CDK8 protein stands as a remarkable solution that exemplifies exceptional quality and meets all my experimental requirements.
I am confident that the CDK8 protein will unlock vital insights into cellular processes, propelling my scientific investigations to new heights.
Its impressive purity and functional characteristics make it an ideal choice for my research endeavors, ensuring reliable and impactful results.
Q&As (5)
Ask a questionCDK8 plays essential roles in normal cellular functions, including development and tissue homeostasis. Its dysregulation, however, is implicated in cancer.
Combination therapies involving CDK8 inhibitors are being explored to enhance treatment outcomes and reduce the likelihood of resistance, providing a more comprehensive approach to cancer management.
CDK8 inhibition can disrupt the cell cycle, slowing down or halting the uncontrolled cell division characteristic of cancer cells, making it a potential therapeutic strategy.
CDK8 can modulate the expression of genes involved in immune response. Understanding its role in the tumor microenvironment may lead to novel immunotherapeutic strategies.
Yes, several clinical trials are underway to assess the safety and effectiveness of CDK8 inhibitors as a targeted therapy for different types of cancer.
Ask a Question for All CDK8 Products
Required fields are marked with *
My Review for All CDK8 Products
Required fields are marked with *
Inquiry Basket